Volume | 5,511,123 |
|
|||||
News | - | ||||||
Day High | 0.574 | Low High |
|||||
Day Low | 0.5505 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Agenus Inc | AGEN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.5564 | 0.5505 | 0.574 | 0.58 | 0.5564 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
8,819 | 5,511,123 | US$ 0.5643095 | US$ 3,109,979 | - | 0.485 - 2.13 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:10:27 | 1 | US$ 0.5602 | USD |
Agenus Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
238.78M | 418.92M | - | 98.84M | -220.29M | -0.53 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Agenus News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AGEN Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.5516 | 0.5797 | 0.525 | 0.5518604 | 4,968,843 | 0.0283 | 5.13% |
1 Month | 0.736 | 0.7763 | 0.485 | 0.6172765 | 7,953,960 | -0.1561 | -21.21% |
3 Months | 0.78 | 0.949 | 0.485 | 0.6667789 | 10,525,347 | -0.2001 | -25.65% |
6 Months | 1.17 | 1.17 | 0.485 | 0.7270802 | 9,814,674 | -0.5901 | -50.44% |
1 Year | 1.60 | 2.13 | 0.485 | 1.00 | 7,307,161 | -1.02 | -63.76% |
3 Years | 2.88 | 6.79 | 0.485 | 2.18 | 5,431,144 | -2.30 | -79.86% |
5 Years | 2.89 | 6.79 | 0.485 | 2.46 | 4,072,272 | -2.31 | -79.93% |
Agenus Description
Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others. |